150 related articles for article (PubMed ID: 36127290)
1. Generalized pairwise comparisons for censored data: An overview.
Deltuvaite-Thomas V; Verbeeck J; Burzykowski T; Buyse M; Tournigand C; Molenberghs G; Thas O
Biom J; 2023 Feb; 65(2):e2100354. PubMed ID: 36127290
[TBL] [Abstract][Full Text] [Related]
2. The net benefit for time-to-event outcome in oncology clinical trials with treatment switching.
Fukuda M; Sakamaki K; Oba K
Clin Trials; 2023 Dec; 20(6):670-680. PubMed ID: 37455538
[TBL] [Abstract][Full Text] [Related]
3. Operational characteristics of generalized pairwise comparisons for hierarchically ordered endpoints.
Deltuvaite-Thomas V; Burzykowski T
Pharm Stat; 2022 Jan; 21(1):122-132. PubMed ID: 34346169
[TBL] [Abstract][Full Text] [Related]
4. A new measure of treatment effect in clinical trials involving competing risks based on generalized pairwise comparisons.
Cantagallo E; De Backer M; Kicinski M; Ozenne B; Collette L; Legrand C; Buyse M; Péron J
Biom J; 2021 Feb; 63(2):272-288. PubMed ID: 32939818
[TBL] [Abstract][Full Text] [Related]
5. Correcting the bias of the net benefit estimator due to right-censored observations.
Péron J; Idlhaj M; Maucort-Boulch D; Giai J; Roy P; Collette L; Buyse M; Ozenne B
Biom J; 2021 Apr; 63(4):893-906. PubMed ID: 33615533
[TBL] [Abstract][Full Text] [Related]
6. An extension of generalized pairwise comparisons for prioritized outcomes in the presence of censoring.
Péron J; Buyse M; Ozenne B; Roche L; Roy P
Stat Methods Med Res; 2018 Apr; 27(4):1230-1239. PubMed ID: 27487842
[TBL] [Abstract][Full Text] [Related]
7. Adjusting win statistics for dependent censoring.
Dong G; Huang B; Wang D; Verbeeck J; Wang J; Hoaglin DC
Pharm Stat; 2021 May; 20(3):440-450. PubMed ID: 33247544
[TBL] [Abstract][Full Text] [Related]
8. Win statistics (win ratio, win odds, and net benefit) can complement one another to show the strength of the treatment effect on time-to-event outcomes.
Dong G; Huang B; Verbeeck J; Cui Y; Song J; Gamalo-Siebers M; Wang D; Hoaglin DC; Seifu Y; Mütze T; Kolassa J
Pharm Stat; 2023 Jan; 22(1):20-33. PubMed ID: 35757986
[TBL] [Abstract][Full Text] [Related]
9. The inverse-probability-of-censoring weighting (IPCW) adjusted win ratio statistic: an unbiased estimator in the presence of independent censoring.
Dong G; Mao L; Huang B; Gamalo-Siebers M; Wang J; Yu G; Hoaglin DC
J Biopharm Stat; 2020 Sep; 30(5):882-899. PubMed ID: 32552451
[TBL] [Abstract][Full Text] [Related]
10. Two-stage estimation to adjust for treatment switching in randomised trials: a simulation study investigating the use of inverse probability weighting instead of re-censoring.
Latimer NR; Abrams KR; Siebert U
BMC Med Res Methodol; 2019 Mar; 19(1):69. PubMed ID: 30935369
[TBL] [Abstract][Full Text] [Related]
11. Correcting for dependent censoring in routine outcome monitoring data by applying the inverse probability censoring weighted estimator.
Willems S; Schat A; van Noorden MS; Fiocco M
Stat Methods Med Res; 2018 Feb; 27(2):323-335. PubMed ID: 26988930
[TBL] [Abstract][Full Text] [Related]
12. Analysis of accelerated failure time data with dependent censoring using auxiliary variables via nonparametric multiple imputation.
Hsu CH; Taylor JM; Hu C
Stat Med; 2015 Aug; 34(19):2768-80. PubMed ID: 25999295
[TBL] [Abstract][Full Text] [Related]
13. Regression with a right-censored predictor using inverse probability weighting methods.
Matsouaka RA; Atem FD
Stat Med; 2020 Nov; 39(27):4001-4015. PubMed ID: 32779274
[TBL] [Abstract][Full Text] [Related]
14. Comparison of baseline covariate adjustment methods for restricted mean survival time.
Hanada K; Moriya J; Kojima M
Contemp Clin Trials; 2024 Mar; 138():107440. PubMed ID: 38228232
[TBL] [Abstract][Full Text] [Related]
15. Model selection for survival individualized treatment rules using the jackknife estimator.
Honvoh GD; Cho H; Kosorok MR
BMC Med Res Methodol; 2022 Dec; 22(1):328. PubMed ID: 36550398
[TBL] [Abstract][Full Text] [Related]
16. On the use of extreme value tail modeling for generalized pairwise comparisons with censored outcomes.
De Backer M; Legrand C; Péron J; Lambert A; Buyse M
Pharm Stat; 2023 Mar; 22(2):284-299. PubMed ID: 36321470
[TBL] [Abstract][Full Text] [Related]
17. On logistic regression with right censored data, with or without competing risks, and its use for estimating treatment effects.
Blanche PF; Holt A; Scheike T
Lifetime Data Anal; 2023 Apr; 29(2):441-482. PubMed ID: 35799026
[TBL] [Abstract][Full Text] [Related]
18. Inverse probability weighted estimators of vaccine effects accommodating partial interference and censoring.
Chakladar S; Rosin S; Hudgens MG; Halloran ME; Clemens JD; Ali M; Emch ME
Biometrics; 2022 Jun; 78(2):777-788. PubMed ID: 33768557
[TBL] [Abstract][Full Text] [Related]
19. Receiver operating characteristic curve estimation for time to event with semicompeting risks and interval censoring.
Jacqmin-Gadda H; Blanche P; Chary E; Touraine C; Dartigues JF
Stat Methods Med Res; 2016 Dec; 25(6):2750-2766. PubMed ID: 24803510
[TBL] [Abstract][Full Text] [Related]
20. The asymptotic distribution of the Net Benefit estimator in presence of right-censoring.
Ozenne B; Budtz-Jørgensen E; Péron J
Stat Methods Med Res; 2021 Nov; 30(11):2399-2412. PubMed ID: 34633267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
